These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28833867)

  • 1. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
    Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
    Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
    Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
    Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Baselga J; Lewis Phillips GD; Verma S; Ro J; Huober J; Guardino AE; Samant MK; Olsen S; de Haas SL; Pegram MD
    Clin Cancer Res; 2016 Aug; 22(15):3755-63. PubMed ID: 26920887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
    Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
    Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
    Fabi A; Alesini D; Valle E; Moscetti L; Caputo R; Caruso M; Carbognin L; Ciccarese M; La Verde N; Arpino G; Cannita K; Paris I; Santini D; Montemurro F; Russillo M; Ferretti G; Filippelli G; Rossello R; Fabbri A; Zambelli A; Leonardi V; D'Ottavio AM; Nisticò C; Stani S; Giampaglia M; Scandurra G; Catania G; Malaguti P; Giannarelli D; Cognetti F
    Breast; 2018 Oct; 41():137-143. PubMed ID: 30092500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment.
    Vilela MD; Longstreth WT; Pedrosa HAS; Gil GOB; Duarte JM; Filho MAD
    World Neurosurg; 2018 Mar; 111():109-114. PubMed ID: 29274446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
    Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
    Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
    Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
    Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
    Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
    Iwata H; Xu B; Kim SB; Chung WP; Park YH; Kim MH; Tseng LM; Chung CF; Huang CS; Kim JH; Chiu JWY; Yamashita T; Li W; Egorov A; Nishijima S; Nakatani S; Nishiyama Y; Sugihara M; Cortés J; Im SA
    Cancer Sci; 2024 Sep; 115(9):3079-3088. PubMed ID: 38979893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
    Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
    Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.